Intranasal migraine drugs

Intranasal Migraine Drugs Market Outlook

The global intranasal migraine drugs market is poised for significant growth, projected to reach approximately USD 2.6 billion by 2025, with a compound annual growth rate (CAGR) of around 8.5% from 2025 to 2033. This growth is primarily driven by the increasing prevalence of migraines, which affects millions of people worldwide, along with the rising demand for effective and rapid relief options. The intranasal route offers distinct advantages such as faster onset of action compared to oral medications, making it a preferred choice for patients who experience acute migraine attacks. Furthermore, the growing awareness of migraine management options and the ongoing research and development in the field of neurological drugs contribute positively to the market dynamics. The trend toward personalized medicine in treating migraines is also expected to support market expansion in the coming years.

Growth Factor of the Market

The growth of the intranasal migraine drugs market is significantly influenced by the increasing awareness and diagnosis of migraine disorders. As healthcare providers become more adept at recognizing and treating migraines, more patients are seeking effective treatment options. Additionally, advances in drug formulation and delivery systems are enhancing the efficacy and patient adherence to intranasal therapies. The convenience of intranasal administration presents a compelling alternative to traditional oral medications, particularly for those who experience nausea or vomiting during migraines. Moreover, the growing trend toward self-medication is fostering demand for over-the-counter intranasal migraine drugs, further propelling market growth. Lastly, the expansion of distribution channels, particularly the rise of online pharmacies, facilitates easier access to these medications for patients globally.

Key Highlights of the Market

• The market is projected to reach USD 2.6 billion by 2025.
• Strong CAGR of 8.5% from 2025 to 2033 indicates robust growth potential.
• Increasing prevalence of migraine disorders drives demand for effective treatments.
• Intranasal delivery offers rapid onset of action, enhancing patient satisfaction.
• Growing self-medication trends leading to increased availability of OTC options.

By Product Type

Triptans:

Triptans represent a significant segment within the intranasal migraine drugs market, primarily due to their specific targeting of serotonin receptors to relieve migraine symptoms effectively. These medications work by constricting dilated blood vessels in the brain and inhibiting the release of pro-inflammatory neuropeptides, which are known to contribute to migraine onset. The rapid action profile of triptans, especially when administered intranasally, is a major draw for patients seeking immediate relief during acute migraine episodes. With their well-established efficacy and safety profiles, triptans remain a first-line treatment option, boosting their market share in the intranasal segment. The continued development of new triptan formulations and delivery mechanisms further strengthens their position in the market.

Ergotamines:

Ergotamines are another critical category of intranasal migraine drugs, renowned for their efficacy in treating acute migraine attacks. This class of drugs derives from the ergot fungus and acts by stimulating alpha-adrenergic and serotonin receptors, effectively reducing headache symptoms. The unique mechanism of action of ergotamines allows them to be effective even when other treatments fail. Although their use has declined in favor of triptans, ergotamines remain a valuable option for patients who do not respond to newer therapies. Their presence in the intranasal market is supported by ongoing research to improve formulations and enhance delivery methods, ensuring they continue to play a relevant role in migraine management.

NSAIDs:

Non-steroidal anti-inflammatory drugs (NSAIDs) form a vital segment of the intranasal migraine drugs market, primarily due to their widespread use and effectiveness in alleviating pain. Intranasal NSAIDs provide a rapid onset of action, which is crucial for patients experiencing acute migraine attacks. These medications work by inhibiting enzymes involved in the inflammatory process, thereby reducing pain and associated symptoms. Their dual role in treating pain while also addressing inflammation makes them highly sought after in migraine management. As patient preferences shift towards non-opioid options, the demand for NSAID formulations, especially in intranasal delivery systems, is expected to grow significantly.

Steroids:

Steroids, while less commonly used for migraine treatment, can play an important role in managing more severe or chronic migraine conditions. The anti-inflammatory effects of steroids can help alleviate migraine-related symptoms and reduce the frequency of attacks. Intranasal steroids offer quick absorption and systemic effects, making them a viable option for acute interventions in certain patients. Research is ongoing to evaluate the use of steroids in conjunction with other migraine therapies, enhancing their application in the market. As the understanding of migraine mechanisms evolves, the potential for steroids to be integrated into comprehensive treatment regimens could lead to an expansion of their usage in the intranasal migraine drugs segment.

Antiemetics:

Antiemetics are critical in the management of migraines, particularly for patients who experience significant nausea and vomiting associated with their attacks. These medications help alleviate nausea, allowing for better tolerance of pain relief therapies. The intranasal route of administration for antiemetics provides rapid relief from these distressing symptoms, enabling patients to manage their migraine episodes more effectively. The growing recognition of the importance of addressing both pain and associated symptoms in migraine management supports the increasing market share of antiemetics. Additionally, the development of new formulations designed for intranasal delivery enhances their attractiveness as a treatment option in the intranasal migraine drugs market.

By Application

Hospitals:

Hospitals serve as a major application segment for intranasal migraine drugs due to the need for immediate treatment in severe cases. Patients often present at emergency departments with acute migraine attacks that require rapid intervention. Intranasal medications are advantageous in such settings because they are easy to administer and provide quick relief. The presence of healthcare professionals ensures optimal dosing and monitoring of patients during treatment, which is especially crucial for those with comorbid conditions. Hospitals are also key in educating patients about proper medication use and managing side effects, facilitating better outcomes in migraine treatment.

Clinics:

Clinics, including specialty headache centers, represent a growing application segment for intranasal migraine drugs. These facilities are dedicated to managing chronic migraine patients through tailored treatment plans involving both medication and lifestyle modifications. The use of intranasal drugs in clinical settings allows for immediate relief during consultations, enhancing the overall patient experience. Clinics often serve as platforms for the empirical assessment of drug efficacy, enabling healthcare providers to adjust treatment plans based on individual patient responses. This personalized approach to migraine management in clinics promotes greater patient adherence and satisfaction, further driving the demand for intranasal therapies.

Homecare Settings:

Homecare settings are increasingly becoming a prominent application area for intranasal migraine drugs, particularly as patients seek convenient and effective solutions for managing their conditions. The ability to self-administer intranasal medications empowers patients to take control of their treatment, leading to a reduction in emergency room visits. Homecare usage is supported by the growing trend toward self-management of healthcare, where patients are encouraged to monitor their symptoms and use medications as needed. This shift not only enhances patient comfort but also underscores the need for effective communication between patients and healthcare providers regarding the appropriate use of intranasal migraine drugs in the home environment.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of intranasal migraine drugs, particularly for acute care settings. These pharmacies ensure that patients receive timely access to medications during their hospital stay, especially when experiencing severe migraine attacks. The advantage of hospital pharmacies lies in their ability to provide immediate dispensing of medications, allowing for rapid treatment initiation. Furthermore, hospital pharmacists often collaborate with healthcare providers to tailor medication regimens based on individual patient needs, supporting optimal outcomes in migraine management. The presence of trained pharmacy staff ensures that patients receive the correct medications and dosing instructions, reinforcing the importance of this distribution channel in the market.

Retail Pharmacies:

Retail pharmacies serve as a vital distribution channel for intranasal migraine drugs, particularly for outpatient management. Patients rely on retail pharmacies for over-the-counter options and prescription medications for managing acute migraines effectively. The accessibility of retail pharmacies enhances patient convenience, allowing them to acquire medications promptly when needed. Additionally, pharmacists in retail settings can offer valuable counseling on medication use, potential side effects, and interactions with other therapies. The increasing prevalence of migraine disorders drives demand for intranasal drugs in retail pharmacies, reinforcing their importance in the overall market landscape.

Online Pharmacies:

Online pharmacies represent an emerging and rapidly growing distribution channel for intranasal migraine drugs, reflecting the broader trend of digitalization in healthcare. The convenience of purchasing medications online appeals to patients who may face mobility issues or prefer the privacy of home delivery. Online platforms provide a wide range of options for patients, including both prescription and over-the-counter intranasal migraine drugs. The ease of access to information regarding product efficacy and pricing enhances the consumer experience. Additionally, the growth of telemedicine and online consultation services further supports the utilization of online pharmacies, as patients can seamlessly obtain prescriptions and order medications from the comfort of their homes.

By Ingredient Type

Sumatriptan:

Sumatriptan is one of the most widely used active ingredients in intranasal migraine therapies, known for its effectiveness in treating acute migraine attacks. This triptan selectively targets serotonin receptors in the brain, helping to alleviate headache pain and associated symptoms such as nausea. The intranasal formulation of sumatriptan provides rapid absorption and onset of action, making it a preferred choice for patients experiencing severe migraines. Sumatriptan's established safety profile and efficacy have led to its popularity among both patients and healthcare providers, contributing significantly to its market share in the intranasal segment. Ongoing research continues to explore enhancements in formulation to improve patient adherence and satisfaction.

Zolmitriptan:

Zolmitriptan is another key ingredient in the intranasal migraine drug market, recognized for its quick action and efficacy in providing relief from acute migraine symptoms. Similar to sumatriptan, zolmitriptan also works by stimulating serotonin receptors, effectively reducing headache intensity and associated symptoms. The intranasal delivery of zolmitriptan enhances patient convenience, especially for those who may struggle with oral medications due to nausea or vomiting. Zolmitriptan is often well-tolerated, with a favorable side effect profile that encourages patient adherence. The continued development of formulations and delivery options for zolmitriptan further supports its competitive position within the market.

Dihydroergotamine:

Dihydroergotamine (DHE) is a well-established ingredient used in the treatment of acute migraines, particularly in patients who do not respond to triptans. As a potent vasoconstrictor, DHE acts by narrowing blood vessels and alleviating headache symptoms. The availability of an intranasal formulation of DHE offers rapid relief and is especially beneficial for patients with severe migraine attacks. DHE’s unique mechanism of action provides an alternative for those who may require more aggressive treatment options. Research continues to explore the optimal dosing strategies and patient selection criteria for employing dihydroergotamine in intranasal therapies, enhancing its role in the migraine management landscape.

Ketorolac:

Ketorolac, a powerful NSAID, is utilized in the intranasal migraine drug market for its strong analgesic properties. It works by inhibiting the synthesis of prostaglandins, thereby reducing pain and inflammation associated with migraines. The intranasal administration of ketorolac offers rapid onset of pain relief, making it a valuable option for patients experiencing acute migraine attacks. Its effectiveness, combined with a favorable safety profile, positions ketorolac as a strong contender in the market. Ongoing studies assess the comparative efficacy of ketorolac against other pain relief options, which may further define its role and market potential in treating migraines.

Metoclopramide:

Metoclopramide, though primarily known as an antiemetic, is also gaining traction in the intranasal migraine drug market for its ability to alleviate nausea associated with migraines. It works by blocking dopamine receptors and enhancing gastric motility, thereby providing symptomatic relief. The intranasal formulation of metoclopramide allows for rapid absorption and quick action, enhancing patient comfort during acute migraine episodes. The integration of metoclopramide with other migraine treatments can improve overall therapeutic outcomes. As understanding of migraine and its associated symptoms evolves, metoclopramide's role in combination therapies is expected to further solidify its place in the market.

By Region

The North American region holds a significant position in the intranasal migraine drugs market, accounting for over 40% of the global market share. This dominance is driven by high prevalence rates of migraine disorders, an extensive healthcare infrastructure, and strong patient awareness regarding treatment options. The region is characterized by substantial investments in research and development, leading to the introduction of innovative intranasal formulations. Furthermore, the trend of self-medication facilitated by online pharmacies has contributed to the growth of this market. North America is expected to witness a robust CAGR of 8.3% during the forecast period, driven by increasing patient demand for effective and convenient migraine relief options.

Europe is also a substantial market for intranasal migraine drugs, capturing around 30% of the global market share. The increasing incidence of migraines across various demographics and the growing acceptance of intranasal therapies are key factors contributing to market growth in this region. European countries are witnessing increased collaboration among pharmaceutical companies and healthcare providers, further driving innovation in drug formulation. The emphasis on improving patient outcomes and enhancing drug accessibility through regulated healthcare systems supports the expansion of intranasal migraine therapies in Europe. The market is anticipated to grow at a CAGR of 7.5% from 2025 to 2033, reflecting the region's strong focus on effective headache management solutions.

Opportunities

The intranasal migraine drugs market is positioned for growth, with several opportunities on the horizon. One of the most significant opportunities lies in the increasing research and development efforts directed at creating new and improved formulations of existing medications. Pharmaceutical companies are investing in novel delivery systems and combination therapies that can enhance the efficacy and patient experience of intranasal drugs. Additionally, the growing acceptance of telemedicine is providing new avenues for patients to obtain prescriptions and manage their conditions conveniently. This trend not only expands the patient base for intranasal therapies but also encourages healthcare providers to explore innovative treatment protocols. Furthermore, the rise in awareness campaigns focused on migraine management can drive demand for effective therapies among patients who previously may not have sought treatment.

Another exciting opportunity exists in the expansion of distribution channels, particularly through online pharmacies. The convenience of purchasing medications online has transformed how patients access treatments, especially for those who prefer discretion in managing their migraines. The integration of e-commerce with telehealth services allows patients to consult healthcare providers and receive prescriptions without the need for in-person visits. This shift opens up new possibilities for pharmaceutical companies to reach a broader audience and cater to the evolving preferences of patients. Moreover, the increasing emphasis on personalized medicine is prompting the development of targeted therapies based on individual patient profiles—an approach that could revolutionize migraine treatment and further drive market growth.

Threats

Despite the positive outlook for the intranasal migraine drugs market, several threats could impact its growth trajectory. One of the primary concerns is the intense competition within the pharmaceutical industry, leading to price pressures and the need for constant innovation. As generic versions of established medications enter the market, they can significantly undercut prices, making it challenging for branded products to maintain market share. Additionally, regulatory hurdles associated with the approval of new drugs can delay the launch of innovative therapies, hindering market growth. Furthermore, the emergence of alternative treatment options, including non-pharmacological therapies such as behavioral interventions and biofeedback, may divert patients away from traditional intranasal medications, impacting overall demand.

Another significant threat lies in the potential for adverse effects and safety concerns related to intranasal medications. Patients may experience side effects that can discourage continued use, leading to decreased adherence to treatment regimens. Moreover, the perception of intranasal therapies as less effective compared to oral medications may present a barrier to acceptance among some patients and healthcare providers. The risk of misuse or overuse of certain intranasal drugs also poses challenges, as it may lead to medication overuse headaches, further complicating treatment protocols. Addressing these threats will require a concerted effort from pharmaceutical companies, healthcare providers, and regulatory bodies to ensure that intranasal migraine therapies remain safe, effective, and widely accepted by patients.

Competitor Outlook

• AbbVie Inc.
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Mylan N.V.
• Impax Laboratories, Inc.
• GlaxoSmithKline plc
• Zogenix, Inc.
• Pfizer Inc.
• Wockhardt Ltd.
• Apotex Inc.
• Sanofi S.A.
• Sandoz Inc.
• AstraZeneca plc
• Hikma Pharmaceuticals PLC

The competitive landscape of the intranasal migraine drugs market is characterized by a mix of established pharmaceutical giants and innovative smaller companies dedicated to advancing treatment options for migraines. Leading companies are heavily investing in research and development initiatives to enhance drug formulations and delivery systems, aiming to improve the patient experience and therapeutic outcomes. The competitive rivalry is intense, with companies striving not only to capture market share but also to differentiate their products through unique value propositions such as rapid onset of action and minimal side effects. Collaborations and partnerships with healthcare providers and research institutions are common strategies employed by these companies to foster innovation and expand their reach in the market.

AbbVie Inc., for example, has made significant strides in the intranasal migraine drugs sector through their advanced research initiatives and commitment to developing novel therapies. Their flagship product, Ubrelvy, showcases the effectiveness of their approach, providing patients with rapid relief from migraine symptoms. Similarly, Eli Lilly and Company has also established a solid position in the market with its portfolio of migraine treatments, including the well-received Emgality. The company’s focus on patient-centric solutions and education continues to drive its market presence and foster loyalty among healthcare providers. Moreover, Teva Pharmaceutical Industries Ltd. leverages its extensive experience in the pharmaceutical industry to offer a range of migraine medications, including both branded and generic options, appealing to a diverse patient population.

Smaller companies, such as Zogenix, Inc., are also making waves in the market by focusing on niche segments and innovative product offerings. Zogenix’s Zohydro and other formulations provide unique solutions aimed at patients seeking alternatives to traditional migraine therapies. The competitive dynamics of the market are further influenced by ongoing clinical trials, regulatory approvals, and patient feedback, all of which shape the development of new products. As companies strive to remain at the forefront of the market, continual adaptation to evolving patient needs and preferences will be instrumental in sustaining growth and maintaining a competitive edge.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Apotex Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sandoz Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sanofi S.A.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Zogenix, Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Wockhardt Ltd.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 AstraZeneca plc
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Eli Lilly and Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Impax Laboratories, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Hikma Pharmaceuticals PLC
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Intranasal migraine drugs Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Homecare Settings
  • 6.2 Intranasal migraine drugs Market, By Product Type
    • 6.2.1 Triptans
    • 6.2.2 Ergotamines
    • 6.2.3 NSAIDs
    • 6.2.4 Steroids
    • 6.2.5 Antiemetics
  • 6.3 Intranasal migraine drugs Market, By Ingredient Type
    • 6.3.1 Sumatriptan
    • 6.3.2 Zolmitriptan
    • 6.3.3 Dihydroergotamine
    • 6.3.4 Ketorolac
    • 6.3.5 Metoclopramide
  • 6.4 Intranasal migraine drugs Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Intranasal migraine drugs Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Intranasal migraine drugs market is categorized based on

By Product Type

• Triptans
• Ergotamines
• NSAIDs
• Steroids
• Antiemetics

By Application

• Hospitals
• Clinics
• Homecare Settings

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Sumatriptan
• Zolmitriptan
• Dihydroergotamine
• Ketorolac
• Metoclopramide

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Mylan N.V.
• Impax Laboratories, Inc.
• GlaxoSmithKline plc
• Zogenix, Inc.
• Pfizer Inc.
• Wockhardt Ltd.
• Apotex Inc.
• Sanofi S.A.
• Sandoz Inc.
• AstraZeneca plc
• Hikma Pharmaceuticals PLC